Correction: Alz Res Therapy 16, 105 (2024)
Following publication of the original article [1], several typographical errors were observed:
-
In Table 2, recurrent ARIA-E for ApoE carriers should be 3.8% (not 11.7%).
-
In Table 2, there were several incorrect indentations for several rows (old and updated versions of Table 2 are presented below).
-
There are two places on page 6 where ‘ARIA-E’ should be ‘ARIA’.
-
In Table 5, the asterisk in right column should be a superscript ‘1’. The footnote should have an end parenthesis at end of the footnote sentence below the table.
Moreover, Supplementary material 1 (.docx) has been replaced with its pdf version with modification in Table S4 - ID21 (the participant should be “male” instead of “female”).
The old version of Table 2:
The updated version of Table 2:
The original article [1] has been updated.
References
Honig LS, Sabbagh MN, van Dyck CH, et al. Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease. Alz Res Therapy. 2024;16:105. https://doi.org/10.1186/s13195-024-01441-8
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1186/s13195-024-01441-8.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Honig, L.S., Sabbagh, M.N., van Dyck, C.H. et al. Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease. Alz Res Therapy 16, 159 (2024). https://doi.org/10.1186/s13195-024-01507-7
Published:
DOI: https://doi.org/10.1186/s13195-024-01507-7